The evidence-based pharmacological treatment of paediatric ADHD

International Journal of Neuropsychopharmacology

Volumn 15, Issue 1, 2012, Pages 27-39

  Vaughan, Brigette S ^a   March, John S ^b   Kratochvil, Christopher J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ADHD; attention; hyperactivity; pharmacotherapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ATOMOXETINE; CLONIDINE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ADOLESCENT DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMORBIDITY; DECREASED APPETITE; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART RATE; HUMAN; INFORMATION RETRIEVAL; IRRITABILITY; LIFESPAN; MEDICAL RESEARCH; NATURAL SELECTION; NEUROBIOLOGY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SEDATION; SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; EVIDENCE BASED MEDICINE; PEDIATRICS; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATOMOXETINE HYDROCHLORIDE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; PEDIATRICS; PROPYLAMINES;

EID: 84856446255     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000095     Document Type: Article

References (87)

1. American Academy of Pediatrics (AAP) (2001). Clinical practice guideline : treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108, 1033-1044.
2. APA (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn)-Text Revision. Washington, DC: American Psychiatric Association.
3. Angold A, Erkanli A, Egger HL, Costello EJ (2000). Stimulant treatment for children : a community perspective. Journal of the American Academy of Child and Adolescent Psychiatry 39, 975-984; discussion 984-994. (Pubitemid 30639785)
4. Asherson P (2005). Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Review of Neurotherapeutics 5, 525-539. (Pubitemid 41021059)
5. Bangs ME, Jin L, Zhang S, Desaiah D, et al. (2008a). Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Safety 31, 345-354. (Pubitemid 351441582)
6. Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, et al. (2008b). Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. Journal of the American Academy of Child and Adolescent Psychiatry 47, 209-218. (Pubitemid 351158789)
7. Barkley RA (1998). Attention-Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment, 2nd edn. New York: The Guilford Press.
8. Barkley RA (2006). Attention-Deficit Hyperactivity Disorder : A Handbook for Diagnosis and Treatment, 3rd edn. New York: Guilford Press.
9. Barkley RA, Fischer M, Edelbrock CS, Smallish L (1990). The adolescent outcome of hyperactive children diagnosed by research criteria : I. An 8-year prospective follow-up study. Journal of the American Academy of Child and Adolescent Psychiatry 29, 546-557. (Pubitemid 20235340)
10. Barkley RA, Fischer M, Smallish L, Fletcher K (2002). The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. Journal of Abnormal Psychology 111, 279-289. (Pubitemid 34441206)
11. Biederman J, Faraone S, Milberger S, Guite J, et al. (1996). A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Archives of General Psychiatry 53, 437-446. (Pubitemid 26149233)
12. Biederman J, Melmed RD, Patel A, McBurnett K, et al. (2008a). Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectrums 13, 1047-1055.
13. Biederman J, Melmed RD, Patel A, McBurnett K, et al. (2008b). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121, e73-e84.
14. Biederman J, Monuteaux MC, Spencer T, Wilens TE, et al. (2008c). Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. American Journal of Psychiatry 165, 597-603. (Pubitemid 351705336)
15. Biederman J, Monuteaux MC, Spencer T, Wilens TE, et al. (2009). Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 124, 71-78.
16. Biederman J, Spencer TJ (2008). Psychopharmacological interventions. Child and Adolescent Psychiatric Clinics of North America 17, 439-458, xi. (Pubitemid 351258358)
17. Bodenheimer T, Wagner EH, Grumbach K (2002a). Improving primary care for patients with chronic illness. Journal of the American Medical Association 288, 1775-1779.
18. Bodenheimer T, Wagner EH, Grumbach K (2002b). Improving primary care for patients with chronic illness : the chronic care model, part 2. Journal of the American Medical Association 288, 1909-1914. (Pubitemid 35168149)
19. Brown RT, Amler RW, Freeman WS, Perrin JM, et al. (2005). Treatment of attention-deficit/hyperactivity disorder : overview of the evidence. Pediatrics 115, e749-e757. (Pubitemid 43843150)
20. Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, et al. (2007). A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biological Psychiatry 61, 694-699. (Pubitemid 46328852)
21. Castellanos FX, Lee PP, Sharp W, Jeffries NO, et al. (2002). Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Medical Association 288, 1740-1748.
22. Castellanos FX, Tannock R (2002). Neuroscience of attentiondeficit/ hyperactivity disorder : the search for endophenotypes. Nature Reviews Neuroscience 3, 617-628. (Pubitemid 135706670)
23. Chappell PB, Riddle MA, Scahill L, Lynch KA, et al. (1995). Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and tourette's syndrome: preliminary clinical experience. Journal of the American Academy of Child and Adolescent Psychiatry 34, 1140-1146.
24. Connor DF (2002). Preschool attention deficit hyperactivity disorder : a review of prevalence, diagnosis, neurobiology, and stimulant treatment. Journal of Developmental and Behavioral Pediatrics 23 (Suppl. 1), S1-S9. (Pubitemid 34211231)
25. Connor DF, Edwards G, Fletcher KE, Baird J, et al. (2003). Correlates of comorbid psychopathology in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 42, 193-200. (Pubitemid 39610599)
26. Cunningham CE, Boyle MH (2002). Preschoolers at risk for attention-deficit hyperactivity disorder and oppositional defiant disorder : family, parenting, and behavioral correlates. Journal of Abnormal Child Psychology 30, 555-569. (Pubitemid 38457415)
27. Daughton JM, Kratochvil CJ (2009). Review of ADHD pharmacotherapies : advantages, disadvantages, and clinical pearls. Journal of the American Academy of Child and Adolescent Psychiatry 48, 240-248.
28. Daviss WB, Birmaher B, Diler RS, Mintz J (2008). Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression? Journal of Child and Adolescent Psychopharmacology 18, 257-264.
29. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J (2001). Preschool children with attention-deficit/hyperactivity disorder : impairments in behavioral, social, and school functioning. Journal of the American Academy of Child and Adolescent Psychiatry 40, 508-515. (Pubitemid 32374267)
30. Durston S, Hulshoff Pol HE, Schnack HG, Buitelaar JK, et al. (2004). Magnetic resonance imaging of boys with attention-deficit/hyperactivity disorder and their unaffected siblings. Journal of the American Academy of Child and Adolescent Psychiatry 43, 332-340. (Pubitemid 41615013)
31. Faraone S (2003). Understanding the effect size of ADHD medications : implications for clinical care. Medscape Psychiatry & Mental Health 8.
32. Faraone SV, Biederman J (2000). Nature, nurture, and attention deficit hyperactivity disorder. Child Development Review 20, 568-581.
33. Faraone SV, Biederman J, Morley CP, Spencer TJ (2008). Effect of stimulants on height and weight: a review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry 47, 994-1009.
34. Faraone SV, Perlis RH, Doyle AE, Smoller JW, et al. (2005). Molecular genetics of attention-deficit/hyperactivity disorder. Biological Psychiatry 57, 1313-1323. (Pubitemid 40798551)
35. Fayyad J, De Graaf R, Kessler R, Alonso J, et al. (2007). Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. British Journal of Psychiatry 190, 402-409. (Pubitemid 46706952)
36. Firestone P, Musten LM, Pisterman S, Mercer J, et al. (1998). Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder : A double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology 8, 13-25. (Pubitemid 28270775)
37. Gittelman R, Landa B, Mattes J, Klein D (1988). Methylphenidate and growth in hyperactive children : a controlled withdrawal study. Archives of General Psychiatry 45, 1127-1130.
38. Gleason MM, Egger HL, Emslie GJ, Greenhill LL, et al. (2007). Psychopharmacological treatment for very young children : contexts and guidelines. Journal of the American Academy of Child and Adolescent Psychiatry 46, 1532-1572. (Pubitemid 350146520)
39. Goldman LS, Genel M, Bezman RJ, Slanetz PJ (1998). Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Journal of the American Medical Association 279, 1100-1107. (Pubitemid 28177819)
40. Gould MS, Walsh BT, Munfakh JL, Kleinman M, et al. (2009). Sudden death and use of stimulant medications in youths. American Journal of Psychiatry 166, 992-1001.
41. Greenhill L, Kollins S, Abikoff H, McCracken J, et al. (2006). Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 45, 1284-1293. (Pubitemid 44665445)
42. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, et al. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry 41 (Suppl. 2), 26S-49S.
43. Hunt RD, Arnsten AF, Asbell MD (1995). An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 34, 50-54.
44. Kaffman M, Sher A, Bar-Sinai N (1979). MBD children-variability in developmental patterns or growth inhibitory effects of stimulants? Israeli Annals of Psychiatry and Related Disciplines 17, 58-66. (Pubitemid 9213936)
45. Kelsey DK, Sumner CR, Casat CD, Coury DL, et al. (2004). Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a doubleblind, placebo-controlled trial. Pediatrics 114, e1-e8.
46. Kessler RC, Adler L, Barkley R, Biederman J, et al. (2006). The prevalence and correlates of adult ADHD in the United States : results from the national comorbidity survey replication. American Journal of Psychiatry 163, 716-723. (Pubitemid 44464584)
47. Kessler RC, Adler LA, Barkley R, Biederman J, et al. (2005). Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biological Psychiatry 57, 1442-1451. (Pubitemid 40798566)
48. Klein RG, Mannuzza S (1988). Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Archives of General Psychiatry 45, 1131-1134. (Pubitemid 19005469)
49. Krain AL, Castellanos FX (2006). Brain development and ADHD. Clinical Psychology Review 26, 433-444.
50. Kratochvil CJ, Greenhill LL, March JS, Burke WJ, et al. (2004). The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder. CNS Drugs 18, 957-966. (Pubitemid 39612007)
51. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL (2008a). Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child and Adolescent Psychiatry and Mental Health 2, 25.
52. Kratochvil CJ, Vaughan BS, Daughton JM, Lubberstedt BD, et al. (2008b). Atomoxetine vs. placebo for the treatment of ADHD in 5-and 6-year-old children. Paper presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, IL, 27-31 October 2008.
53. Lahey BB, Pelham WE, Loney J, Kipp H, et al. (2004). Three-year predictive validity of DSM-IV attention deficit hyperactivity disorder in children diagnosed at 4-6 years of age. American Journal of Psychiatry 161, 2014-2020. (Pubitemid 39441401)
54. Lahey BB, Pelham WE, Stein MA, Loney J, et al. (1998). Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. Journal of the American Academy of Child and Adolescent Psychiatry 37, 695-702. (Pubitemid 28304532)
55. Lavigne JV, Gibbons RD, Christoffel KK, Arend R, et al. (1996). Prevalence rates and correlates of psychiatric disorders among preschool children. Journal of the American Academy of Child and Adolescent Psychiatry 35, 204-214. (Pubitemid 26039700)
56. Madaan V, Kinnan S, Daughton J, Kratochvil CJ (2006). Innovations and recent trends in the treatment of ADHD. Expert Review of Neurotherapeutics 6, 1375-1385. (Pubitemid 44596133)
57. Mannuzza S, Klein RG, Truong NL, Moulton III JL, et al. (2008). Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. American Journal of Psychiatry 165, 604-609. (Pubitemid 351705337)
58. CDC 2005. Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder-United States, 2003. Morbidity and Mortality Weekly Report 54 842-847.
59. Michelson D, Adler L, Spencer T, Reimherr FW, et al. (2003). Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry 53, 112-120. (Pubitemid 36126473)
60. Michelson D, Allen AJ, Busner J, Casat C, et al. (2002). Oncedaily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder : a randomized, placebo-controlled study. American Journal of Psychiatry 159, 1896-1901. (Pubitemid 35283256)
61. Michelson D, Faries D, Wernicke J, Kelsey D, et al. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder : a randomized, placebo-controlled, dose-response study. Pediatrics 108, E83.
62. Mostofsky SH, Cooper KL, Kates WR, Denckla MB, et al. (2002). Smaller prefrontal and premotor volumes in boys with attention-deficit/hyperactivity disorder. Biological Psychiatry 52, 785-794.
63. MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Archives of General Psychiatry 56, 1073-1086.
64. MTA Cooperative Group (2004). National institute of mental health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113, 762-769.
65. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, et al. (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder : acute comparison and differential response. American Journal of Psychiatry 165, 721-730. (Pubitemid 351810541)
66. Perrin JM, Friedman RA, Knilans TK (2008). Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122, 451-453.
67. Pliszka S (2007). Practice parameter for the assessment and treatment of children and adolescents with attentiondeficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 46, 894-921.
68. Pliszka SR (2003). Non-stimulant treatment of attentiondeficit/ hyperactivity disorder. CNS Spectrums 8, 253-258.
69. Pliszka SR, Liotti M, Bailey BY, Perez III R, et al. (2007). Electrophysiological effects of stimulant treatment on inhibitory control in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 17, 356-366. (Pubitemid 47067959)
70. Powers RL, Marks DJ, Miller CJ, Newcorn JH, et al. (2008). Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome. Journal of Child and Adolescent Psychopharmacology 18, 449-459.
71. Safer D, Allen R, Barr E (1975). Growth rebound after termination of stimulant drugs. Pediatrics 86, 113-116.
72. Sallee FR, Lyne A, Wigal T, McGough JJ (2009a). Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 19, 215-226.
73. Sallee FR, McGough J, Wigal T, Donahue J, et al. (2009b). Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder : a placebocontrolled trial. Journal of the American Academy of Child and Adolescent Psychiatry 48, 155-165.
74. Scahill L, Chappell PB, Kim YS, Schultz RT, et al. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry 158, 1067-1074. (Pubitemid 32623110)
75. Spencer T, Heiligenstein JH, Biederman J, Faries DE, et al. (2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry 63, 1140-1147. (Pubitemid 36084059)
76. Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, et al. (2007). Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. Journal of Child and Adolescent Psychopharmacology 17, 689-700.
77. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, et al. (2005). Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 116, e74-e80.
78. Swanson J, Arnold LE, Kraemer H, Hechtman L, et al. (2008). Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the multimodal treatment study of children with ADHD (MTA): Part II : supporting details. Journal of Attention Disorders 12, 15-43.
79. Swanson JM, Ruff DD, Feldman PD, Furr AJ, et al. (2005). Characterization of Growth in Children with ADHD. Paper presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, 18-23 October 2005.
80. Weiss M, Tannock R, Kratochvil C, Dunn D, et al. (2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 44, 647-655. (Pubitemid 40875359)
81. Wigal SB, Gupta S, Greenhill L, Posner K, et al. (2007). Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 17, 153-164. (Pubitemid 46828911)
82. Wigal SB, McGough JJ, McCracken JT, Biederman J, et al. (2005). A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. Journal of Attention Disorders 9, 275-289. (Pubitemid 41551759)
83. Wigal T, Greenhill L, Chuang S, McGough J, et al. (2006). Safety and tolerability of methylphenidate in preschool children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 45, 1294-1303. (Pubitemid 44665446)
84. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, et al. (2005). Validity of the executive function theory of attentiondeficit/hyperactivity disorder : a meta-analytic review. Biological Psychiatry 57, 1336-1346. (Pubitemid 40798553)
85. Winterstein AG, Gerhard T, Shuster J, Johnson M, et al. (2007). Cardiac safety of central nervous system stimulants in children and adolescents with attentiondeficit/hyperactivity disorder. Pediatrics 120, e1494-e1501. (Pubitemid 350223669)
86. Winterstein AG, Gerhard T, Shuster J, Zito J, et al. (2008). Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in medicaid database. Annals of Pharmacotherapy 42, 24-31.
87. Woodruff TJ, Axelrad DA, Kyle AD, Nweke O, et al. (2004). Trends in environmentally related childhood illnesses. Pediatrics 113 (Suppl. 4), 1133-1140. (Pubitemid 38437367)